Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
Aprea Therapeutics (Nasdaq: APRE), a clinical-stage biopharmaceutical company specializing in precision oncology through synthetic lethality, has announced its participation in the Maxim 2024 Healthcare Virtual Summit. Dr. Oren Gilad, President and CEO of Aprea, will be presenting at two sessions during the event, which is scheduled from October 15 to 17, 2024.
The first presentation will be part of the Precision and Immune Oncology Panel on Wednesday, October 16, from 2:00 - 3:00 PM ET. This will be followed by a Fireside Chat on Thursday, October 17, from 3:30 - 4:00 PM ET. The conference will be hosted live on M-Vest, and interested parties can access the presentations by signing up for M-Vest membership.
Aprea Therapeutics (Nasdaq: APRE), un'azienda biofarmaceutica in fase clinica specializzata in oncologia di precisione tramite letalità sintetica, ha annunciato la sua partecipazione al Maxim 2024 Healthcare Virtual Summit. Il Dr. Oren Gilad, Presidente e CEO di Aprea, presenterà in due sessioni durante l'evento, che si svolgerà dal 15 al 17 ottobre 2024.
La prima presentazione sarà parte del Precision and Immune Oncology Panel mercoledì 16 ottobre, dalle 14:00 alle 15:00 ET. Seguirà un Fireside Chat giovedì 17 ottobre, dalle 15:30 alle 16:00 ET. La conferenza sarà trasmessa in diretta su M-Vest, e le parti interessate possono accedere alle presentazioni registrandosi come membri di M-Vest.
Aprea Therapeutics (Nasdaq: APRE), una empresa biofarmacéutica en etapa clínica especializada en oncología de precisión a través de la letalidad sintética, ha anunciado su participación en el Maxim 2024 Healthcare Virtual Summit. El Dr. Oren Gilad, Presidente y CEO de Aprea, presentará en dos sesiones durante el evento, que está programado del 15 al 17 de octubre de 2024.
La primera presentación será parte del Precision and Immune Oncology Panel el miércoles 16 de octubre, de 2:00 a 3:00 PM ET. Esto será seguido por un Fireside Chat el jueves 17 de octubre, de 3:30 a 4:00 PM ET. La conferencia se transmitirá en vivo a través de M-Vest, y las partes interesadas pueden acceder a las presentaciones suscribiéndose como miembros de M-Vest.
Aprea Therapeutics (Nasdaq: APRE), 합성 치사성을 통한 정밀 종양학에 전문화된 임상 단계의 생명공학 회사가 Maxim 2024 Healthcare Virtual Summit에 참여한다고 발표했습니다. Aprea의 사장 겸 CEO인 오렌 길라드 박사가 2024년 10월 15일부터 17일까지 예정된 행사 중 두 세션에서 발표할 예정입니다.
첫 번째 발표는 10월 16일 수요일 오후 2시부터 3시까지 진행되는 Precision and Immune Oncology Panel의 일환으로 진행됩니다. 이 후에는 10월 17일 목요일 오후 3시 30분부터 4시까지 진행되는 Fireside Chat이 이어집니다. 회의는 M-Vest를 통해 생중계될 예정이며, 관심 있는 분들은 M-Vest 회원 가입을 통해 발표에 접근할 수 있습니다.
Aprea Therapeutics (Nasdaq: APRE), une entreprise biopharmaceutique en phase clinique spécialisée dans l'oncologie de précision par le biais de la létalité synthétique, a annoncé sa participation au Maxim 2024 Healthcare Virtual Summit. Le Dr Oren Gilad, Président et CEO d'Aprea, présentera lors de deux sessions pendant l'événement, qui est prévu du 15 au 17 octobre 2024.
La première présentation fera partie du Precision and Immune Oncology Panel le mercredi 16 octobre, de 14h00 à 15h00 ET. Cela sera suivi d'un Fireside Chat le jeudi 17 octobre, de 15h30 à 16h00 ET. La conférence sera diffusée en direct sur M-Vest, et les parties intéressées peuvent accéder aux présentations en s'inscrivant comme membres de M-Vest.
Aprea Therapeutics (Nasdaq: APRE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf präzise Onkologie durch synthetische Letalität spezialisiert hat, hat seine Teilnahme am Maxim 2024 Healthcare Virtual Summit bekannt gegeben. Dr. Oren Gilad, Präsident und CEO von Aprea, wird in zwei Sitzungen während der Veranstaltung präsentieren, die vom 15. bis 17. Oktober 2024 geplant ist.
Die erste Präsentation wird Teil des Precision and Immune Oncology Panels am Mittwoch, den 16. Oktober, von 14:00 bis 15:00 Uhr ET sein. Darauf folgt ein Fireside Chat am Donnerstag, den 17. Oktober, von 15:30 bis 16:00 Uhr ET. Die Konferenz wird live auf M-Vest übertragen, und interessierte Parteien können über eine Mitgliedschaft bei M-Vest auf die Präsentationen zugreifen.
- None.
- None.
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024.
Presentation Details
| Session: | Precision and Immune Oncology Panel |
| Date/ time: | Wednesday, October 16, 2:00 - 3:00 PM ET |
| Session: | Fireside Chat |
| Date/ time: | Thursday, October 17, 3:30 - 4:00 PM ET |
This conference will be hosted live on M-Vest. To access the above presentations, sign up to become an M-Vest member.
Click here to reserve your seat
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website https://aprea.com/.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
When is Aprea Therapeutics (APRE) presenting at the Maxim 2024 Healthcare Virtual Summit?
What topics will Aprea Therapeutics (APRE) discuss at the Maxim 2024 Healthcare Virtual Summit?
How can investors access Aprea Therapeutics' (APRE) presentations at the Maxim 2024 Healthcare Virtual Summit?
Who will be representing Aprea Therapeutics (APRE) at the Maxim 2024 Healthcare Virtual Summit?
